Dual PD-1/CTLA-4 inhibition improves outcomes in several cancers but remains limited by toxicity. A recent article reports the first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody, demonstrating durable responses, but dose-dependent immune-related adverse events were also observed. This commentary examines whether the bispecific format meaningfully improves the therapeutic index and considers priorities for the next phase of development.
Park et al. (Wed,) studied this question.